JP2013501071A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501071A5
JP2013501071A5 JP2012523941A JP2012523941A JP2013501071A5 JP 2013501071 A5 JP2013501071 A5 JP 2013501071A5 JP 2012523941 A JP2012523941 A JP 2012523941A JP 2012523941 A JP2012523941 A JP 2012523941A JP 2013501071 A5 JP2013501071 A5 JP 2013501071A5
Authority
JP
Japan
Prior art keywords
composition
stabilizing amount
linaclotide
item
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012523941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/044522 external-priority patent/WO2011017502A2/en
Publication of JP2013501071A publication Critical patent/JP2013501071A/ja
Publication of JP2013501071A5 publication Critical patent/JP2013501071A5/ja
Withdrawn legal-status Critical Current

Links

JP2012523941A 2009-08-06 2010-08-05 リナクロチドを含む処方物 Withdrawn JP2013501071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23172509P 2009-08-06 2009-08-06
US61/231,725 2009-08-06
PCT/US2010/044522 WO2011017502A2 (en) 2009-08-06 2010-08-05 Linaclotide-containing formulations for oral administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015025192A Division JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Publications (2)

Publication Number Publication Date
JP2013501071A JP2013501071A (ja) 2013-01-10
JP2013501071A5 true JP2013501071A5 (enExample) 2013-09-12

Family

ID=43544939

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523941A Withdrawn JP2013501071A (ja) 2009-08-06 2010-08-05 リナクロチドを含む処方物
JP2015025192A Pending JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015025192A Pending JP2015098476A (ja) 2009-08-06 2015-02-12 リナクロチドを含む処方物

Country Status (5)

Country Link
US (4) US8748573B2 (enExample)
JP (2) JP2013501071A (enExample)
CA (1) CA2770077A1 (enExample)
MX (2) MX2012001660A (enExample)
WO (1) WO2011017502A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120213846A1 (en) * 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
HRP20192207T1 (hr) * 2010-08-11 2020-02-21 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
HUE032237T2 (en) * 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
WO2014088623A1 (en) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Linaclotide compositions
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2015166468A1 (en) * 2014-05-02 2015-11-05 Sinoveda Canada, Inc. Formulas comprising highly soluble elements and vitamin d for the prevention and treatment of bowel conditions during calcium supplementation
US10272131B2 (en) 2014-08-11 2019-04-30 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
US11572386B2 (en) * 2014-09-08 2023-02-07 Auro Peptides Ltd. Process for the preparation of linaclotide
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
US20180008547A1 (en) * 2015-02-02 2018-01-11 Aurobindo Pharma Ltd Stable Compositions comprising Linaclotide
EP3302440B1 (en) * 2015-06-05 2021-01-06 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide
JP2018529749A (ja) * 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
TWI795462B (zh) * 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
CN116098864B (zh) * 2023-04-11 2023-06-09 北京普诺旺康医药科技有限公司 一种利那洛肽干混悬剂及其制备方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) * 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JPS63146828A (ja) * 1986-07-18 1988-06-18 Chugai Pharmaceut Co Ltd 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
JPH03505334A (ja) 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) * 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
CZ433898A3 (cs) 1996-07-03 1999-04-14 Alza Corporation Nevodné protické peptidové formulace
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) * 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
EP1098636A1 (en) 1998-07-23 2001-05-16 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
ID29085A (id) 1998-11-27 2001-07-26 Kanji Takada Suatu formulasi oral untuk penghantaran obat gastrointestinal
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
IL153688A0 (en) * 2000-06-28 2003-07-06 Teva Pharma Carvedilol
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002026248A1 (en) 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
EP1351704B1 (en) 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
GB0104371D0 (en) * 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
WO2003014304A2 (en) 2001-08-09 2003-02-20 Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International Protonic formulation
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP1458407A1 (en) * 2001-12-21 2004-09-22 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
CN1726012A (zh) 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放
ATE477268T1 (de) * 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE390142T1 (de) * 2003-05-14 2008-04-15 Indus Biotech Pvt Ltd Synergistische zusammensetzung zur behandlung von diabetes mellitus
ATE553747T1 (de) * 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
CN101094651B (zh) 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
WO2007022531A2 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP1996218A4 (en) * 2006-02-24 2012-07-11 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
ITMI20060629A1 (it) * 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
AU2007272272B2 (en) 2006-07-10 2012-04-12 Pba3 Biomed Gmbh Antimicrobial peptides
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2661521C (en) 2006-08-31 2016-04-12 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
EP2114379A2 (en) * 2006-12-20 2009-11-11 Bayer HealthCare LLC Factor vii and viia compositions
EP2650303A1 (en) 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US20120213846A1 (en) 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
US20120039949A1 (en) * 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
AU2009322285B2 (en) 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2770334A1 (en) * 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide

Similar Documents

Publication Publication Date Title
JP2013535505A5 (enExample)
CN1149993C (zh) 莫西沙星药物制剂
US11833255B2 (en) Nanoparticles with pH triggered drug release
US20180105430A1 (en) Generation of mesoporous materials using multiphase surfactant systems
HRP20140807T1 (hr) Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b
JP2012136541A5 (enExample)
EP3046547A1 (en) Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo
JP2008518950A5 (enExample)
EP2981249A1 (en) Mesoporous alum nanoparticles as universal platform for antigen adsorption, presentation, and delivery
EP3512554A1 (en) Platelet compositions and methods for the delivery of therapeutic agents
US20120328568A1 (en) Compositions and uses of lectins
JP2013510169A5 (enExample)
CA3019769C (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2016527202A5 (enExample)
CN111467351A (zh) 用于治疗疾病的方法
JP2018509388A5 (enExample)
JP2014524444A5 (enExample)
RS60986B2 (sr) Režimi doziranja melflufena za kancer
JP2024532810A (ja) 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
WO2024131833A1 (en) Mrna-based hpv+ cancer vaccines, and uses thereof
JP2016512247A5 (enExample)
JP2011510667A5 (enExample)
US20250222082A1 (en) Protein and peptide vaccines targeting methanogens
US20230226211A1 (en) Cd25-targeted il-2 for increasing cd4 t cell formation and treatment of infections
JP2013503148A5 (enExample)